{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T11:10:10Z","timestamp":1744888210809,"version":"3.40.4"},"reference-count":0,"publisher":"Royal Pharmaceutical Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1211\/pj.2025.1.353908","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T10:42:36Z","timestamp":1744886556000},"source":"Crossref","is-referenced-by-count":0,"title":["NICE recommends cladribine for treating active relapsing forms of multiple sclerosis"],"prefix":"10.1211","member":"162","container-title":["Pharmaceutical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T10:42:36Z","timestamp":1744886556000},"score":1,"resource":{"primary":{"URL":"https:\/\/pharmaceutical-journal.com\/article\/news\/nice-recommends-cladribine-for-treating-active-relapsing-forms-of-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1211\/pj.2025.1.353908","relation":{},"ISSN":["2053-6186"],"issn-type":[{"value":"2053-6186","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}